ranibizumab
Sign in to saveAlso known as RFB002, rhuFab V2, RG-3645, Rhufab, FAB-12 Variant Y0317
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Key facts
- Drug.type
- mab
- Drug.mab_type
- Fab
- Drug.source
- zu/o
- Drug.target
- Vascular endothelial growth factor A (VEGF-A)
- Drug.tradename
- Lucentis, others
- Drug.MedlinePlus
- a607044
- Drug.DailyMedID
- Ranibizumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravitreal injection
- Drug.ATC_prefix
- S01
- Drug.ATC_suffix
- LA04
- Drug.biosimilars
- Byooviz, Cimerli, Epruvy, Nufymco, Ranivisio, Raniviz, Ranopto, Rimmyrah, Susvimo, Ximluci ranibizumab-eqrn, ranibizumab-leyk, ranibizumab-nuna
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Research
7,511 papers- Ranibizumab for myopic choroidal neovascularization.Expert opinion on biological therapy · 2020
- Ranibizumab.Drugs · 2007
- Ranibizumab: A Review in Retinopathy of Prematurity.Paediatric drugs · 2021
- Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.Ophthalmology · 2012
- Ranibizumab for the treatment of diabetic retinopathy.Expert opinion on biological therapy · 2021
via PubMed
~9 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- Interactions
- Pharmacology
- Society and culture
- Legal status
- Biosimilars
- Economics
- References
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis. Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006, and in the European Union in January 2007.
Excerpted from Wikipedia’s “ranibizumab” article, available under the CC BY-SA 4.0 licence.